Short term efficacy and safety of PD-1 inhibitor and apatinib plus S-1 and oxaliplatin as neoadjuvant chemotherapy for patients with locally advanced gastric cancer
Yunchuan Tang,Li Dai,Zhiqin Wang,Meifeng Zhang,Haitao Xie,Yunshan Yang,Yongjin Zhou,Zhiqiang Yan,Haibin Wang,Hongxin Yang,Lei Zhang,Tong He,Jiaju Chen,Guanghai Wang,Xiangren Jin,Qian Wang
DOI: https://doi.org/10.1097/md.0000000000040572
IF: 1.6
2024-11-28
Medicine
Abstract:Gastric cancer (GC) is 1 of the most common malignant tumors worldwide. Many patients are already in the advanced stage at the time of initial diagnosis, and the prognosis of those with locally advanced gastric cancer (LAGC) is poor. [ 1 ] The treatment for GC is comprehensive and is based on surgery. After years of research and development, radical gastrectomy with D2 lymph node dissection has become the standard surgical procedure for patients with resectable GC. Despite the standard plan of D2 lymph node dissection plus chemotherapy, the prognosis of patients with LAGC remains poor even after the complete resection of primary tumors and regional lymph nodes. [ 2 ] Prospective randomized controlled studies have reported that systemic chemotherapy extends the survival of patients with LAGC. A study observed that nivolumab plus chemotherapy resulted in significant improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy alone in patients with GC. [ 3 ] SOX regimen as neoadjuvant chemotherapy is associated with high efficacy, acceptable adverse effect, and increased rate of D2 lymph nodes dissection and R0 resection. Another study found that apatinib combined with SOX was an effective and safe neoadjuvant therapy for LAGC. [ 2 ] Forty patients underwent surgery, with an R0 resection rate of 75.0%, a radiologic response rate of 75%, and a T downstaging rate of 36.4%. Such clinical studies have made a breakthrough in the efficacy of LAGC treatment. However, neoadjuvant data from related studies are lacking, and the literature is scarce. From another perspective, these data support the rationale of using PD-1 inhibitor and apatinib plus S-1 and oxaliplatin for treating LAGC.
medicine, general & internal